The Claim
In adults with type 2 diabetes, once-weekly exenatide reduces the composite risk of all-cause death or hospitalization for heart failure by 11%, with a hazard ratio of 0.89 (95% CI 0.80–0.99), based on data from a randomized controlled trial involving 14,752 patients followed for a median of 3.2 years, with consistent benefit across the overall population and a meaningful reduction in major cardiovascular morbidity and mortality.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking a weekly diabetes shot called exenatide may help lower the chance of dying or ending up in the hospital with heart failure for people with type 2 diabetes.
See the scientific wording
Once-weekly exenatide reduces the composite risk of all-cause death or hospitalization for heart failure by 11% in adults with type 2 diabetes, with a hazard ratio of 0.89 (95% CI 0.80–0.99), based on data from a randomized controlled trial of 14,752 patients followed for a median of 3.2 years. This benefit is consistent across the overall population and reflects a meaningful reduction in major cardiovascular morbidity and mortality.
What the research says
1 studyThe study found that once-weekly exenatide reduced the combined risk of dying or being hospitalized for heart failure by 11%, just as claimed, especially in people who didn’t already have heart failure.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.